SCHEMBL2273186

SCHEMBL2273186

O=C(O)c1ccc(-c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.68
DHODH Q02127 1/20 0.68
MEN1 O00255 2/20 0.64
PKM P14618 2/20 0.64
KMT2A Q03164 2/20 0.64
MAPT P10636 1/20 0.64
GRIK1 P39086 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
HDAC2 Q92769 6/20 0.61
HDAC1 Q13547 3/20 0.61
HDAC3 O15379 1/20 0.60
SERPINE1 P05121 1/20 0.58
SUCNR1 Q9BXA5 1/20 0.58
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
PTPN1 P18031 1/20 0.53
PDCD1 Q15116 1/20 0.52
CD274 Q9NZQ7 1/20 0.52
KDM4D Q6B0I6 1/20 0.52
KDM4C Q9H3R0 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275453 0.94 ACLY (0.76) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2270222 0.94 DHODH (0.77) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2269268 0.93 ACLY (0.67) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2269341 0.90 HDAC2 (0.71) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2274974 0.90 ACLY (0.67) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2272605 0.88 DHODH (0.73) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2272049 0.88 ACLY (0.78) ACLYDHODHMEN1PKMKMT2A
SCHEMBL4563581 0.88 ACLY (0.65) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2278459 0.88 HDAC2 (0.71) ACLYDHODHMEN1PKMKMT2A
SCHEMBL2275720 0.88 SUCNR1 (0.73) ACLYDHODHMEN1PKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885DHODH 1469/4885MEN1 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.